公开(公告)号：US20220315954A1

公开(公告)日：2022-10-06

申请号：US17658217

申请日：2022-04-06

申请人： Sasya Inc.

发明人： Goutham Vemuri ,  Christopher Lindsay ,  Kevin Roberg-Perez ,  Christopher D. Snow ,  Elizabeth A. Cameron

IPC分类号： C12P7/16 ,  C12N9/04 ,  C12N1/20

摘要： The biological production of beta-hydroxyisovalerate (βHIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active βHIV metabolic pathway for the production of βHIV. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

公开(公告)号：US20220325304A1

公开(公告)日：2022-10-13

申请号：US17658214

申请日：2022-04-06

申请人： Sasya Inc.

发明人： Goutham Vemuri ,  Christopher Lindsay ,  Kevin Roberg-Perez ,  Christopher D. Snow ,  Elizabeth A. Cameron

IPC分类号： C12P7/16 ,  C12N9/88 ,  C12N9/04 ,  C12N15/52

摘要： The biological production of beta-hydroxyisovalerate (βHIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active βHIV metabolic pathway for the production of βHIV. Alternatively, the non-natural enzyme can be a βHIV synthase used to produce βHIV in a cell-free environment. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

公开(公告)号：US11920177B2

公开(公告)日：2024-03-05

申请号：US17658217

申请日：2022-04-06

申请人： Sasya Inc.

发明人： Goutham Vemuri ,  Christopher Lindsay ,  Kevin Roberg-Perez ,  Christopher D. Snow ,  Elizabeth A. Cameron

IPC分类号： C12P7/16 ,  C12N1/20 ,  C12N9/04 ,  C12N9/88 ,  C12N15/52

CPC分类号： C12P7/16 ,  C12N1/20 ,  C12N9/0006 ,  C12N9/88 ,  C12N15/52 ,  C12Y101/01086

摘要： The biological production of beta-hydroxyisovalerate (βHIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active βHIV metabolic pathway for the production of βHIV. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.